From the Editor

One can only learn the secrets of "fight club" by attending its meetings.

More than anything else MonkeyPox and COVID-19 have shown that we are interdependent, no matter what continent you call home.

As winter approaches, the next generation of COVID-19 vaccines are being prepared and scheduled, ready for distribution across Europe and the world.

Promising applications for targeted delivery may be cresting the horizon.

GSK has completed its demerger of Haleon and has signed an agreement to help support future pandemic preparedness in Europe.

As we reach further afield in the molecular universe, we encounter new types of problems to resolve.

Dame Deborah James’ legacy and the millions raised through her campaigning will undoubtedly be a big boost to clinical research, ultimately providing new and promising treatments for bowel cancer patients.

Cases of monkeypox are rising around the world, but it is unlikely the virus will become a pandemic problem.

Lions and tigers and monkeypox, oh my!

A long-running criminal case involving the theft of confidential data from a pharma giant is still unravelling, as more convictions are made.

Fresh insight is instrumental in the discussion of novel analytics.

The AMR Action Fund has made its first investments, marking an important step forward for the partnership to achieve its goal of bringing new treatments to the market for priority pathogens.

3D cell cultures could provide key avenues to unlocking critical information.

As Russia’s invasion of Ukraine continues, industry leaders speak out in condemnation of the actions taking place and pledge to provide aid to those in need.

Borrowing is good, but invention is best.

As company revenues are gaining a boost from COVID-19, the issue of pricing is being debated once more.

The process of reshaping inevitably leads to fresh insights.

Overall, 2021 proved to be another good year for drug approvals in Europe, albeit with a slight disappointment for Alzheimer’s patients, but what should industry be watching out for in 2022?

January is the kind of month that can make your head spin.

Pharma and biotech are ruling the roost in terms of university innovation, but European spinouts are still experiencing barriers to long-term success.

We have broken rules, invented new ones, and engineered stronger institutions and supply chains that will serve us better going forward.

Manufacturing capacity expansion is high on the agenda for many bio/pharma companies and service providers in Europe.

Change of roster does not change the goal line. We are all patients first.

While the players may change, pharma’s patients-first focus should not.

Excessive drug pricing is being scrutinized across Europe, as hefty fines are set to send out a clear message of intolerance to anti-competition conduct.

Congress questions FDA on plans to catch up and move forward with facility inspections.

Vaccines define the path to putting the pandemic in the rear-view mirror.

Five therapeutic candidates for the treatment of COVID-19 are identified as promising by the European Commission.